Article
Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.
The pharmacogenomics journal - 1 Jan 2005
Swan G E, Valdes A M, Ring H Z, Khroyan T V, Jack L M, Ton C C, Curry S J, McAfee T
Abstract excerpt
The A1 allele of the dopamine D2 receptor gene (DRD2) is associated with a reduced number of dopamine binding sites in the brain and with the increased likelihood of substance abuse and addictive behavior. In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.